Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Silence Therapeutics’ potential not recognised by the market, says FD Silence Therapeutics’ (LON:SLN) finance director Tim Freeborn suggests the market is not picking up on the potential of the company’s ‘gene silencing’ technology. New York-listed Alnylam Pharmaceuticals, which has a market value of almost US$1.5bn, is one of Silence’s closest peers, targeting liver cancer. Freeborn says Silence, whose platform technologies can be used to turn off faulty genes, has the potential to tackle a wider array of diseases than its American peer yet is valued at just US$50mln (£33mln). Freeborn said: “These other companies have been spending hundreds of millions of dollars a year, year after year, and Silence’s burn is a fraction of what they are spending. “And yet we think we’re either level with them or doing better – so that’s why we’re hopeful.”
You are right , that might explain all the large trades that have been going on. No one would put down that amount of cash as a pure speculation, not even rich Germans ! My experience with Germans is the opposite. They are very careful with their money.They will not spend ( or invest ) unless they know that they can get double, if not more ,the amount back in return.
is going on over here ? 13.11k 18.40k 13.80k 11.50k 11.50k That is........ 68.31k .......all BUYS !! Now who would spend all that money on a share ? They must have some knowledge others do not have considering that the share price moved down today !
Why try to compare ARM to INTC ? They are both very good companies., ARM still has a lot in it , do not write it off. The best option is to hold both shares that way you would be getting the best of both.GL
Bought 2,576,620 shares @ 5.20 .......value 133.90k Now that is what I call a large trade........... Who would throw away that kind of money on a worthless share ?? These large trade mean people believe that SLN is on to somthing good.
Bridge will be hosting a call for analysts, which is scheduled for 12 noon today, 8th March 2013. In order to obtain dial-in access code details, please register at Jessica.Allum@fticonsulting.com. Tom Reynolds, CEO of Bridge Energy, commented: "I am pleased to announce this positive step forward on Asha, which clearly underlines the commerciality of this discovery; less than one month after our resource update and three months after drilling. "With existing estimates indicating more than 13 mmboe net recoverable to Bridge from Asha, this Agreement both accelerates and unlocks significant value within PL457. In addition to the Asha discovery further upside potential exists on this licence within the independent Aglaja and Amol prospective targets." - Ends -
Biotech company Silence Therapeutics rose 0.9p or 22 per cent to 4.95p after receiving approval from mega strict German regulator, Federal Institute for Drugs and Medical Devices, for trials of its pancreatic cancer drug. Silence also said it was reviewing financing options for an aggressive expansion. The trials will test Silence’s ATU027 compound, which prevents the spread of cancer from one organ to another, in combination with Gemcitabine, an anti-tumour drug. Silence is considered by experts to be in an excellent position to crystallise inherent value in its potentially ‘game changing’ RNA-based technology and that makes the stock appear dirt cheap. Read more: http://www.thisismoney.co.uk/money/markets/article-2288680/MARKET-REPORT-Luxury-brand-Herm-s-tipped-bag-Mulberry-neat-1-5bn-share-tumble-fuels-sale-speculation.html#ixzz2MksU0GgE Follow us: @MailOnline on Twitter | DailyMail on Facebook
At it again with his trusted follower to recommend his post, just ignore. The market and the BOD know what they are doing. Ignore
All bios need time .Pity the ones who panicked yesterday , but why sell when there was no bad news ? This share has a lot of good in it. It is working on something which is very new and unique so why listen to those who know nothing about the subject. With bios it is best to remember that holding shares in bio caompanies does not turn one into a scientist !.
Tue, 5th Mar 2013 10:11 March 5 (Reuters) - Biotech research and development company Silence Therapeutics said it received approval from German authorities for trials of its pancreatic cancer drug and was reviewing financing options for an aggressive expansion. Shares in the company rose as much as 20 percent on the London Stock Exchange on Tuesday. The trials will test Silence's ATU027 compound, which prevents the spread of cancer from one organ to another, in combination with Gemcitabine, an anti-tumour drug. Silence also said latest studies have shown that its new lipid formulation, DBTC, is effective for RNAi (ribonucleic acid interference) treatments to liver tissues. The company said it was actively looking at an aggressive expansion of its platform, drug targets and key personnel. Silence said the Federal Institute for Drugs and Medical Devices (BfArM) in Germany had encouraged the company to apply the trials as a combination therapy for a wide range of cancers. (Reporting By Abhirup Roy and Ankur Banerjee in Bangalore; Editing by Joyjeet Das)
I always say and repeat " a little knowledge is a dangerous thing ". All those who sold because of your writing yesterday must be regretting it. Let the ones who are in charge work and do the " talking " .In their case they DO have the knowhow !!
That is the reason I told you yesterday to stop acting like " a know all ". Bio companies cannot afford to spend cash on something which will not deliver. In cases like this it is " always the scientsit who knows best. " so give them time and they will deliver. Going about rubbishing all the hard work these bios do is to say the least stupid. The reason I told them to ignore your postings yesterday. Seems I was right !!
Tue, 5th Mar 2013 09:00 RNS Number : 2404Z Silence Therapeutics PLC 05 March 2013 Silence Therapeutics plc ("Silence" or the "Company") Business Update ATU027 Silence Therapeutics is delighted to report it has received formal approval from the German authorities (BfArM) for its phase 1b/2a combination trial into pancreatic cancer. The trial will test Silence's Atu027 anti-metastatic compound in combination with Gemcitabine, the leading anti-tumour drug. It is expected that the 1b element of the trial will last for 3 months and the 2a element scheduled to begin in July 2013 and ending approximately in July 2014. BfArM has also encouraged Silence, primarily due to the exceptional safety profile of ATU027 in phase 1, to apply for 1b/2a trials using Atu-027 as a combination therapy across a wide range of cancers. It indicated that these further trials could be run broadly in parallel with pancreatic cancer. ATU027 is now the most advanced RNAi Oncology program in the world and has a novel anti-metastatic effect which results in preventing extravasation and intravasation of cancer cells. This is in contrast to conventional cancer drugs which target the primary tumour and are non-specific for metastasis. Other Indications Separately, Silence is delighted to report excellent results from proof of concept studies in acute liver injury. The work was carried out at the University of Rostock under Professor Brigitte Vollmar. Crucially the studies showed that Silence's new lipid formulation, DBTC, is effective at delivering RNAi treatments to liver tissues. On the basis of this success as well as other results, Silence is moving ahead with plans to target non oncology indications including orphan and rare diseases. Business Update The company is of the belief that RNAi based therapeutics are on the cusp of a new wave of drug development, better delivery platforms and capital investment. This has been borne out by recent clinical trials as well as significant public and private equity deals. Silence Therapeutics is the only company worldwide who can effectively deliver siRNAs to multiple locations in the human body. Together with the strong patent position in its' synthetic siRNA, AtuRNAi, Silence Therapeutics is amongst a handful of companies who have the freedom to operate in this space. As a result of the above factors, the company is actively looking at an aggressive expansion of its platform, drug targets and key personnel. The company and its major shareholders are reviewing the financing options in respect of this expansion. Current cash stands at c. £8.0m.
You asked if any of the major holders bought at 7p. Are you implying that they would be happy if the share had to move back to 7p and stop there ? I am sure that they are looking for a much greater return for all the cash they put in !
sorry wrong board
Just stick to the share you " Love " and do not try to act the wise guy on other boards. It will help this share if you stop acting as if this share is the one and only !! Your posts on other boards always backfire .
Do you really think that you are the only one who can " research " a share ? Do y ou think these major shareholders did not read and get all the details that they could before parting with theri money. We are talking of big amounts here. they must have liked what they found, they would not have bought otherwise. Funny they did not ask for your help ! It seems that the information they were given was better than what you are giving !
Did you buy in at 7p ? Is that why you are angry ?
Ignore inanaco read this ! MARKET REPORT: Silence shares will be golden Shop broker Singer Capital Markets says it is now well positioned to attempt to crystallise inherent value in its potentially ‘game changing’ RNA-based technology. Silence specialises in technology that shuts down target genes by a process known as RNAi interference, which could in turn stop diseases from forming. With a market value of only £33m, it has a portfolio of treatments which apparently puts its US peers in the shade. Regulus Therapeutics, soon to float on Nasdaq with a valuation of around £150m makes Silence look dirt cheap. Shrewd investors have been piling into the stock of late now that the company is in the best of health. A notable fan is Richard Griffiths, the entrepreneur and former boss and founder of Evolution Securities. He continues to fill his boots and now sits on 7.1 per cent or 103.9m shares
Just ignore, do not give him the pleasure . he will stop if you ingnore him. I am sure that your BOD kow more than inanaco about their product . Ignore him !